Download PDF
Klin Padiatr 2023; 235(04): 221-227
DOI: 10.1055/a-2041-2986
Original Article

Identification of ADA as a Biomarker for Atypical Epstein Barr Virus Infection in Children

Ting Shi
1   Department of Infectious Diseases, Soochow University Affiliated Children’s Hospital, Suzhou, China
,
Linlin Huang
2   Pediatric Intensive Care Unit, Soochow University Affiliated Children’s Hospital, Suzhou, China
,
Wangsheng Zhang
1   Department of Infectious Diseases, Soochow University Affiliated Children’s Hospital, Suzhou, China
,
Wenxin Shi
1   Department of Infectious Diseases, Soochow University Affiliated Children’s Hospital, Suzhou, China
,
Jiahui Wu
1   Department of Infectious Diseases, Soochow University Affiliated Children’s Hospital, Suzhou, China
,
Yuanxi Bian
1   Department of Infectious Diseases, Soochow University Affiliated Children’s Hospital, Suzhou, China
,
Yanqun Jiang
1   Department of Infectious Diseases, Soochow University Affiliated Children’s Hospital, Suzhou, China
,
Jianmei Tian
1   Department of Infectious Diseases, Soochow University Affiliated Children’s Hospital, Suzhou, China
› Author Affiliations Funding Information Natural Science Foundation of Suzhou City — http://dx.doi. org/10.13039/100016803; SKJY2021106
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective This study aims to explore the ability of adenosine deaminase (ADA) to discriminate atypical Epstein Barr virus (EBV) infection in children from acute febrile illness.

Methods All children admitted to the Children’s Hospital of Soochow University between 2018 and 2019, who were acute febrile patients and subjected to the plasma EBV-DNA polymerase chain reaction (PCR) and indirect immunofluorescence (IIF) assay for EBV-specific antibodies assays. The diagnostic value of each detection index was compared by the area under the ROC curve.

Results In children with atypical Epstein Barr virus infection, the sensitivity, specificity, positive predictive value, negative predictive value and Youden index were 62.87%, 100.00%,100.00%, 61.73% and 0.63 for EBV-DNA PCR assay, 80.84%, 100.00%, 100.00%, 75.76% and 0.81 for VCA-IgG avidity and 89.22%, 87.00%, 91.98%, 82.86% and 0.76 for ADA. VCA-IgG avidity (AUC=0.904, P<0.01) and ADA (AUC=0.881, P<0.01) assays had the great diagnostic efficiency. In addition, the sensitivity, specificity and AUC were 92.75%,91.43% and 0.921(95%CI: 0.856–0.985) for ADA in the course≤3 days group, respectively.

Conclusions ADA has a good diagnostic value in the early stage of atypical EBV infection, and is not affected by primary EBV infection and reactivation.

Schlüsselwörter Adenosine deaminase, Epstein -Barr virus, Biomarker, children.

Key words

Adenosine deaminase - Epstein-Barr virus - Biomarkerpublished online 2023


Publication History

Article published online:
28 April 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 de Thé G, Day N, Geser A. et al. Epidemiology of the Epstein-Barr virus infection and associated tumors in man. Bibl Haematol 1975; 216-220
    PubMedGoogle Scholar
  • 2 Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10: 803-821
    CrossrefPubMedGoogle Scholar
  • 3 Balfour HH, Verghese P. Primary Epstein-Barr virus infection: impact of age at acquisition, coinfection, and viral load. J Infect Dis 2013; 207: 1787-1789
    CrossrefPubMedGoogle Scholar
  • 4 Dowd JB, Palermo T, Brite J. et al. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010. PLoS One 2013; 8: e64921
    CrossrefPubMedGoogle Scholar
  • 5 Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492
    CrossrefPubMedGoogle Scholar
  • 6 Nowalk A, Green M. Epstein-Barr virus. Microbiol Spectr 2016; 4
    PubMedGoogle Scholar
  • 7 Shi T, Huang L, Chen Z. et al. Characteristics of primary Epstein-Barr virus infection disease spectrum and its reactivation in children, in Suzhou, China. J Med Virol 2021; 93: 5048-5057
    CrossrefPubMedGoogle Scholar
  • 8 Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med 2007; 120: 911.e1-8
    CrossrefPubMedGoogle Scholar
  • 9 Kanakry JA, Hegde AM, Durand CM. et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood 2016; 127: 2007-2017
    CrossrefPubMedGoogle Scholar
  • 10 Antonioli L, Colucci R, La Motta C. et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr Drug Targets 2012; 13: 842-862
    CrossrefPubMedGoogle Scholar
  • 11 Mejer J, Nygaard P, Cohn J. et al. Adenosine deaminase, purine nucleoside phosphorylase and 5’-nucleotidase activities in infectious mononucleosis. Adv Exp Med Biol 1984; 165: 249-252
    CrossrefPubMedGoogle Scholar
  • 12 Schiavetti A, Gonfiantini M, Varrasso G. et al. Atypical Epstein-Barr-virus infection in a 5-year-old girl. Minerva Pediatr 2009; 61: 115-117
    PubMedGoogle Scholar
  • 13 Shi J, Ma W, Li W. Epidemiologic features of children with Epstein-Barr virus associated diseases in Hangzhou, China. J Med Virol 2020; 92: 1277-1282
    CrossrefPubMedGoogle Scholar
  • 14 Niller HH, Bauer G. Epstein-Barr virus: clinical diagnostics. Methods Mol Biol 2017; 1532: 33-55
    CrossrefPubMedGoogle Scholar
  • 15 AbuSalah M, Gan SH, Al-Hatamleh M. et al. Recent advances in diagnostic approaches for Epstein-Barr virus. Pathogens 2020; 9: 226
    CrossrefPubMedGoogle Scholar
  • 16 Shi T, Huang L, Luo L. et al. Diagnostic value of serological and molecular biological tests for infectious mononucleosis by EBV in different age stages and course of the disease. J Med Virol 2021; 93: 3824-3834
    CrossrefPubMedGoogle Scholar
  • 17 Singh L, Javali M, Mehta A. et al. Study of cerebrospinal fluid levels of lactate, lactate dehydrogenase and adenosine deaminase in the diagnosis and outcome of acute meningitis. Neurol Res 2022; 44: 463-467
    CrossrefPubMedGoogle Scholar
  • 18 Delemarre EM, van Hoorn L, Bossink A. et al. Serum biomarker profile including CCL1, CXCL10, VEGF, and adenosine deaminase activity distinguishes active from remotely acquired latent tuberculosis. Front Immunol 2021; 12: 725447
    CrossrefPubMedGoogle Scholar
  • 19 Bruu AL, Hjetland R, Holter E. et al. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies. Clin Diagn Lab Immunol 2000; 7: 451-456
    CrossrefPubMedGoogle Scholar
  • 20 Zavialov AV, Gracia E, Glaichenhaus N. et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 2010; 88: 279-290
    CrossrefPubMedGoogle Scholar
  • 21 Ghaderi B, Amini S, Maroofi F. et al. Adenosine deaminase activity in chronic lymphocytic leukemia and healthy subjects. Iran J Cancer Prev 2016; 9: e5069
    CrossrefPubMedGoogle Scholar
  • 22 Naval-Macabuhay I, Casanova V, Navarro G. et al. Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. J Leukoc Biol 2016; 99: 349-359
    CrossrefPubMedGoogle Scholar